Also known as: melanomas
Melanoma is an aggressive skin cancer that develops from melanocytes and carries substantial metastatic potential if diagnosed late. Early detection is associated with markedly better outcomes.
Moderna and Merck's personalized mRNA cancer vaccine, intismeran autogene, showed promising Phase 3 results in preventing melanoma recurrence. Combined with Keytruda, it cut recurrence risk by half and reduced spread by 59% in earlier data. The treatment could reach patients within two years pending regulatory approval.
Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda significantly reduced melanoma recurrence risk in a Phase 3 trial. The FDA has not yet approved the vaccine, with potential availability expected by early 2027.
Merck and Moderna announced that their personalized mRNA cancer vaccine intismeran, combined with Keytruda, slowed melanoma recurrence in a late-stage trial. It is the first randomized Phase 3 trial to prove the benefit of neoantigen vaccines.
Perspective Therapeutics plans May 2026 analyst event, Q1 results, and conference appearances. The radiopharmaceutical firm is advancing 212Pb-based therapies in Phase 1/2a trials and expanding facilities.
Recent studies have uncovered new cancer therapeutic targets and strategies, including self-assembling antibody-drug conjugates, a dual-action metabolic drug, and a BRAF protein structure. Research also advanced on dendritic cell vaccines, the origins of a rare childhood leukemia, and cancer cachexia treatment.
New research links gut microbiome composition to cancer immunotherapy outcomes. A 674-patient study showed gut bacteria predict melanoma recurrence with up to 94% accuracy, while other studies identified specific microbes influencing treatment response and resistance in melanoma and liver cancer.
Moderna posted Q2 2026 revenue of $145 million and a GAAP net loss of $0.8 billion, while improving its 2026 spending outlook. Its norovirus candidate missed Phase 3 interim criteria, and mFLUSIVA faces an August 5 PDUFA decision.
KEYNOTE-942 five-year data: intismeran autogene plus Keytruda reduced melanoma recurrence risk by 49% and kept 68.8% of patients cancer-free versus 49.1% with Keytruda alone. Distant metastasis or death risk fell 59%.
A phase one trial of RSO-021 achieved disease control in 67% of relapsed mesothelioma patients. Other advances include daraxonrasib for NRAS-driven melanoma, an aneuploidy biomarker for PARP inhibitor response in childhood cancers, and new research into a cancer target and cholangiocarcinoma treatment.
Moderna shares fell 11% on Friday, eyeing their worst week since August 2025 after a June surge. An FDA panel voted 9-0 for its mRNA-1010 flu vaccine, with a decision due by August 5.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07761871 |
Exercise and Nutritional Intervention in Patients With Melanoma Receiving Immunotherapy |
RECRUITING | NA |
| NCT07720726 |
Impact of Dysport on PMFF Donor Scar |
NOT_YET_RECRUITING | PHASE4 |
| NCT07704918 |
Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma |
RECRUITING | NA |
| NCT07696715 |
Timing of Immunotherapy in Melanoma |
RECRUITING | NA |
| NCT07686835 |
Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma. |
RECRUITING | PHASE2 |
| NCT07660666 |
Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor |
NOT_YET_RECRUITING | NA |
| NCT07651020 |
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors |
COMPLETED | |
| NCT07649252 |
A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan |
COMPLETED | |
| NCT07644897 |
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma |
RECRUITING | PHASE2 |
| NCT07628634 |
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors |
RECRUITING | EARLY_PHASE1 |
